Propensity-score matching with GAN-generated observations from electronic health

records: simulation study and application to the evaluation of prone positioning in

COVID-19 patients under mechanical ventilation

Bertrand Bouvarel[1,2], Benjamin Glemain[1,2], Fabrice Carrat[1,2], Nathanael Lapidus[1,2]

[1] Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique

IPLESP, F75012 Paris, France

[2]AP-HP.Sorbonne Université, Public Health Department, Saint-Antoine Hospital, F75012 Paris,

France

Corresponding author: Bertrand Bouvarel – Mail: bouvarel.bertrand@gmail.com

11   Phone: +33 6 41 96 05 59

Abstract

Background

Propensity score (PS) methods are widely used in observational studies to estimate causal effects, but they often exclude patients due to a lack of comparable counterparts, leading to reduced power and potential bias. Generative adversarial networks (GANs) have shown promise in creating synthetic data, but their application to causal inference remains underexplored. Synthetic data could be used as plausible counterfactuals, potentially mitigating the issues of the PS methods.

This study evaluates the integration of GAN-generated synthetic observations into propensity score matching (PSM) to improve the emulation of RCTs, using both simulated and real-world electronic health record (EHR) data.

Methods

A simulation study was conducted using with predefined confounding structures to compare traditional PSM against two hybrid approaches incorporating GAN-generated synthetic patients to partially or fully match the original sample of patients. Treatment effects were estimated via logistic regression, and performance was assessed by bias, standard error, alpha risk, power, and confidence interval coverage. The methods were applied to a real-world dataset of mechanically ventilated COVID-19 patients to evaluate the impact of early prone positioning on 28-day mortality.

Results

In simulations, GAN-generated patients permitted to match all patients in the original sample, whereas PSM dropped up to 60% of them. While synthetic augmentation improved sample size, unadjusted use of synthetic matches led to underestimated standard errors and inflated type I error. Down-weighting matched synthetic data improved error control but did not consistently outperform PSM in bias or power. In the real-world application (n=1399), treatment effect estimates for prone positioning were similar across all methods and did not reach statistical significance.

Conclusion

GAN-augmented propensity score matching can reduce sample loss. However, it's current application in causal inference through PS matching remains limited. Synthetic data do not contribute independent information and must be cautiously integrated to avoid misleading precision. While promising, current GAN implementations require methodological refinements before routine use in causal inference.

Keywords: observational study, causal inference, propensity score matching, simulation, neural networks, generative adversarial networks, electronic health records

Background

Randomized controlled trials (RCTs) are regarded as the gold standard for evaluating interventions because randomization balances both measured and unmeasured confounders between treatment. [1] This balance permits causal attribution of outcome differences to the intervention. However, RCTs have well-known limitations. [2, 3] They are often expensive and time-consuming to conduct, especially for large populations or multiple sites. Ethical and practical constraints (e.g. the principle of equipoise) can preclude randomizing patients to certain exposures, particularly if early evidence or clinical judgment suggests one treatment might be superior. Additionally, RCT participants are usually managed under strict protocols in controlled settings, which may limit the generalizability of trial findings to broader real-world patient. [4]

In contrast, vast amounts of real-world data are now captured in electronic health records (EHRs). Over the past decade, EHR systems have enabled the aggregation of rich clinical data on millions of patients, including demographics, diagnoses, treatments, and outcomes. [5, 6] These EHR databases represent valuable resources for observational studies of treatment effects in diverse, routine-care populations. By analyzing EHR cohorts, researchers can address questions that might not be feasible in RCTs due to ethical or logistical reasons. [7, 8] However, because treatments in EHR data are not randomly assigned, observational analyses are vulnerable to confounding by indication and other biases. Patients receiving a given treatment may differ systematically from those who do not, and these differences (e.g., disease severity, comorbidities) can themselves affect outcomes, therefore simple comparisons of treated vs. untreated outcomes in such data can be very misleading, and such databases represent a valuable but yet scarcely used resource for the implementation of therapeutic evaluation.

Causal inference methods have been developed to explore causal hypotheses using observational

data. [9] These methods are mainly based on counterfactual approaches via the construction of a

propensity score (PS). [10] Two main PS-based strategies are frequently used: (1) inverse

probability of treatment weighting (IPTW), [11] which reweights patients to create a pseudo-

population with balanced covariates, and (2) propensity-score matching (PSM), [12, 13] which pairs

treated and untreated patients with similar propensity scores and discards unmatched individuals.

When properly applied, these techniques can mimic the randomized allocation of interventions that

prevent confounding by indication in RCTs and reduce bias in estimated treatment effects from

observational data.

The use of these methods with EHR data has already been proposed [14] using classical machine

learning models. Despite the promising results of some studies, several limitations remain. Due to

the nature of the data, in observational studies based on patients treated with knowledge of their

symptoms/pathology, some patients may end up with a very high or low probability of receiving

treatment (i.e., propensity scores very close to 0 or 1) because their clinical characteristics strongly

predict treatment with very few, if any, counterfactual patients in other treatment groups. [15] Due

to the violation of the positivity assumption, standard PSM must discard those patients due to lack

of matches, with resultant power loss and selection bias, and IPTW must assign very large weights

to a few rare patients, which inflates variance and leads to unstable estimates, especially when

considering rarely-used treatments. [16]

One potential solution is to leverage modern machine learning to generate synthetic

"counterfactual" patient data for the under-represented treatment group. In recent years, thanks to

the improvement of algorithms and their support, neural networks have become increasingly

popular for exploiting large databases [17, 18]. Among these networks, generative adversarial

networks (GAN) are widely used thanks to their ability to generate realistic data. [19] A GAN

consists of a *generator* network that produces artificial data (e.g. patient records) and a

discriminator network that attempts to distinguish synthetic data from real data. [20]

Through adversarial training, the generator learns to create increasingly lifelike outputs that the

discriminator cannot easily detect as fake. GANs were initially popularized for image generation,

but have since been applied to many domains including healthcare data. [21]

For example, researchers have used GANs to generate synthetic electronic health records and

claims data that preserve important statistical properties of the originals. [22] Synthetic health data

can facilitate data sharing and augment analyses while protecting patient privacy. [23] Specialized

GAN architectures (e.g. medGAN, CTGAN) have been developed to handle tabular clinical data

with mixed types (continuous, categorical). CTGAN in particular has demonstrated good

performance in modeling complex multimodal distributions in patient records. [24] These

advancements raise the question of whether GANs can be used to generate plausible counterfactual

patients (e.g., a synthetic untreated version of a treated patient) to improve causal inference.

In this study, we propose to integrate GAN-generated synthetic observations into a propensity score

matching framework and to study the impact on causal inference. We first conducted a simulation

study to evaluate this approach under controlled conditions, examining whether matching with

GAN data can recover known "true" treatment effects, in comparison with PSM. We then applied

the method to a motivating example – the effect of early prone positioning on mortality in severe

COVID-19 under mechanical ventilation – using EHR data from a large hospital network.

Methods

Simulation study

We designed a simulation study to compare traditional propensity-score matching with GAN-augmented matching methods. The overall workflow was as follows: (1) simulate "true" patient datasets with a known causal structure; (2) train a GAN on each dataset to generate synthetic patients; (3) perform different matching strategies (with and without synthetic data) to estimate the treatment effect; and (4) repeat across many simulations to evaluate performance.

Simulated data generation

Each simulated dataset consisted of 2000 patients with 8 baseline variables: 6 binary covariates representing patient characteristics (X_1–X_6), 1 binary treatment indicator (T) and 1 binary outcome (Y) for each hypothesis. Details about the simulation parameters are given in **Supplementary Text 1**.

We constructed the simulation so that treatment assignment was confounded by the baseline covariates, mimicking an observational study. Specifically, in *balanced* scenarios we set $P(T = 1) = 50\%$, while in *unbalanced* scenarios $P(T = 1) = 20\%$. The probability of treatment was modeled as a logistic function of certain covariates to introduce confounding by indication. We considered four underlying hypotheses for the data-generating process, depicted as directed acyclic graphs in **Figure 1**. Null hypotheses H0a and H0b considered that the treatment had no effect on the outcome. For H0a, the outcome was present with a 30% probability, independently of all other variables, whereas for H0b, the occurrence of the outcome depended on baseline characteristics. Alternative hypotheses H1a and H1b considered that the treatment had an effect on the outcome

(log odds ratio [OR] = 0.1), with H1b implying additional associations of the outcome with baseline

characteristics. A sensitivity analysis was conducted with a higher effect size for H1a and H1b (log

OR = 0.5). For each hypothesis, 1000 independent datasets were simulated.

Note: In this article, we distinguish "simulated" patients (those directly generated by our known

simulation process) vs. "synthetic" ones (GAN-generated observations created from a simulated

dataset).

Figure 1. Directed acyclic graphs representing the 4 hypotheses of simulated causal associations.

X: baseline characteristics of patients, T: treatment, Y: outcome.

GAN model for synthetic patient generation

After creating each simulated dataset, we used a GAN to generate additional synthetic patient

records. Among considered architectures available for generating discrete or tabular data (mixture

of discrete and continuous data), [25] we selected the CTGAN, specifically designed for tabular

data and able to handle mixed continuous and categorical variables effectively. [24] [26] In our

implementation, we simplified the data to binary features only, to ease the learning problem. We

used the open-source Synthetic Data Vault (SDV) to train the CTGAN on each simulated

dataset. [27] For each simulated dataset of 2,000 patients, we trained CTGAN until convergence

(using default hyperparameters from SDV) and then generated a large pool of 50,000 synthetic

patient records. This sizable pool was intended to include a wide variety of plausible patients drawn

from the same underlying distribution as the original data. In particular, we expected that for most

real patients in the dataset, one or more "counterfactual" synthetic patients could be found (i.e., a

synthetic patient with very similar covariates but the opposite treatment value). We evaluated the

fidelity of the GAN generation by comparing marginal and pairwise distributions between the

simulated and synthetic samples.

Treatment effect estimation

The treatment effect on the outcome was estimated with univariable logistic regression. Propensity

scores were constructed via multiple logistic regression, using baseline characteristics as

predictors. The R MatchIt package [28] was used to match observations in the opposite treatment

group and similar propensity scores, without replacement and using a caliper of 0.25. Three

frameworks, depicted in **Figure 2**, were used to define the analyzed datasets:

-    Propensity-score matching (PSM): construction of a PS in the initial simulated dataset and

inclusion of pairs of treated/untreated patients with similar PS without relying on synthetic

patients (any patient who did not have a match in the other treatment group was excluded);

-    Partial hybrid matching (PHM): inclusion of the same pairs of simulated patients as for the

PSM method, and addition of "hybrid pairs," i.e. PS-matching of previously unmatched

simulated patients with synthetic patients (PS in synthetic patients is calculated by applying

to their baseline covariates the PS model derived from the simulated dataset);

-    Full hybrid matching (FHM): PS-matching of all patients in the simulated dataset with

synthetic patients, resulting in hybrid pairs exclusively.

Figure 2. Diagram of the three frameworks of matching of the observation with similar propensity score.

PS: propensity score, Tr.: treated, not Tr.: not treated.

Synthetic observations were generated using data from the simulated dataset and cannot be

considered as independent from simulated observations. If treated as ordinary observations, the

inclusion of such generated data would therefore increase the sample size without the additional

information expected from independently sampled observations, and consequently underestimate

the standard errors of log odds ratio (OR) in the FHM and PHM frameworks. To address this

issue, we weighted the observations so that (i) the sum of weights in the analyzed dataset equaled

the number of simulated observations, and (ii) both observations in a given pair had the same

weight to avoid confounding by indication. Weights were therefore set to 0.5 for synthetic

observations and their matched simulated observations, and 1 for all other observations. In a

sensitivity analysis, weights were set to 0.25 for all synthetic observations and their matched

simulated observations, with a sum of weights consequently lower than the number of simulated

observations, whatever the number of synthetic observations.

Performance Metrics

The performances of these methods were assessed by evaluating their ability to correctly estimate

the simulated treatment effect over 1000 simulated datasets. Judgment criteria were the bias

(average difference between simulated and estimated log OR), the average standard error, the

empirical standard error (standard deviation of the log OR point estimates), the type 1 error (alpha

risk) and the statistical power (proportion of simulations with 95% confidence intervals (CIs)

excluding 0 for null and alternative hypotheses, respectively), and the 95% CI coverage (proportion

of 95% CIs containing the simulated effect) for alternative hypotheses. Additionally, we tracked the

matched sample size (number of matched pairs) for each method. PSM drops patients to achieve

balance, whereas PHM/FHM aim to retain more patients by using synthetic matches. We estimated how many more simulated patients could be kept by hybrid approaches.

Motivating example: evaluation of prone positioning in COVID-19 mechanically-ventilated patients

Prone positioning – placing a patient in the face-down position – is a therapeutic intervention used in mechanically ventilated patients with acute respiratory distress syndrome (ARDS) in intensive care units (ICUs) to improve oxygenation. Its effectiveness in reducing mortality among patients with severe ARDS was demonstrated in a landmark randomized controlled trial in 2013. [29] Since then, further randomized investigations into its effectiveness in patient subgroups have been limited for ethical reasons, as its overall benefit in the ARDS population had already been established.

In this study, we applied the aforementioned methods to an observational EHR dataset to assess the effect of prone positioning on 28-day mortality in patients with severe ARDS caused by COVID-19. Specifically, we investigated whether GAN-augmented matching could lead to different conclusions or greater precision compared to standard propensity score matching. This analysis is compared to the target RCT it tried to emulate in **Supplementary Table 1**.

Study participants

Assistance Publique–Hôpitaux de Paris (AP-HP) is the university hospital trust operating in Grand

Paris, receiving more than 10 million annual patient visits in 39 hospitals. A healthcare data

warehouse ("Entrepôt de Données de Santé" AP-HP https://eds.aphp.fr) was set up in 2015 to

conduct non-interventional research based on data collected during patients' stays. [30] This

database gathers clinical data, biology and microbiology tests, imaging data, prescriptions, textual

data, as well as diagnoses coded with the International Classification of Diseases Version 10 (ICD-

10) and medical procedures coded with the Classification commune des actes médicaux (CCAM).

Data were extracted from this warehouse to retrieve all the patients who had performed a PCR test

for SARS-CoV-2 with a validated result in any AP-HP hospital, which represents a dataset of

more than one million patients.

Eligible patients were COVID-19 positives, as described in **Supplementary Table 1**, with

respiratory distress requiring mechanical ventilation within 48 hours after ICU admission. Only

patients admitted between March 1, 2020 and December 31, 2020 were selected (corresponding

broadly to patients from the first and second waves, prior to vaccine availability). In this analysis,

patients are defined as "treated" if prone positioning was initiated within 48 hours after ICU

admission, whereas "control" patients were those without early prone positioning. Patients who

died in the first 48 hours were excluded from the analysis, as we assumed that their critical state at

admission would be an exclusion criterion from an RCT addressing the same question. The follow-

up period started 48 hours after admission and ended after 28 days or death, whichever occurred

first. A linkage of the data warehouse with the national database of deceased persons, provided by

the National Institute of Statistics and Economic Studies (Insee), permitted assessment of vital

status even after a patient was discharged from ICU. The judgment criterion for this analysis was

28-day mortality.

Variable selection and imputation

A broad set of variables available in the EHR data were selected to enter the analysis. These

included risk factors commonly associated with COVID-19 morbidity and mortality, [31, 32]

likely to be used for PS modeling, as well as miscellaneous variables describing patients'

conditions and characteristics, necessary for GAN generation. Those included biological

measurements, medical procedures during hospitalization, or comorbidities, for a total of 50

variables. A detailed list of selected variables is provided in **Supplementary Table 2**, with their

distribution in the treated and control groups. All variables were defined at baseline (within 48

hours following ICU admission).

Multiple imputation by chained equations was used to handle variables subject to missing values,

using predictive mean matching for continuous variables and logistic regression for binary

variables. [33, 34] Ten imputed datasets were created and independently used for synthetic patients

generation and treatment effect estimation, using the previously described PSM, PHM and FHM

frameworks. The distribution of selected variables after multiple imputation is reported in

Supplementary Table 3. Continuous variables were binarized after imputation prior to data

generation, to simplify the learning process of the CTGAN algorithm and avoid possible generated

outliers, with threshold values chosen according to their deemed association with survival

(**Supplementary Table 4**). The same estimation methods as those described in the simulation

study were used to estimate the treatment effect in each imputed dataset. Treatment effect

estimates (log OR) were finally pooled using Rubin's rule.

Standardized differences were calculated to assess the balanced distribution of patient

characteristics between intervention groups, with a threshold of 0.1 designated to indicate clinically

meaningful imbalance. Positivity assumptions were assessed graphically by plotting the distribution

of the propensity score in both intervention groups.

Results

Simulation study

Matched sample size

On average among 1000 simulations, the PSM results relied on approximately 711 pairs out of the

2000 simulated patients, i.e. a 28.9% loss of unmatched patients. The PHM and FHM frameworks,

with balanced treatment allocation and 0.5 weights for patients in hybrid pairs, allowed to

additionally match 577 simulated patients with synthetic ones, lessening the patients loss to 0.05%

of the initial sample. This means a "counterfactual" generated patient could be found for almost all

simulated patients, thus preserving the initial sample under all H0 and H1 hypotheses. With

unbalanced treatment allocation, the patients loss for PSM was 60.2%, while PHM and FHM

allowed to match most simulated patients with synthetic patients (0.015% and 0.01% loss,

respectively).

 Simulations under the null hypothesis

Results are reported in **Table 1**. Under the H0a and H0b hypotheses (absence and presence of

confusion, respectively, with no treatment effect), the biases for usual PSM methods with balanced

treatment allocation were -0.004 and 0.034, and the estimated alpha risks were 0.037 and 0.063,

respectively. The biases for PHM were -0.002 and 0.035 under H0a and H0b, with alpha risks of

0.083 and 0.107, respectively. The biases for FHM were -0.003 and 0.039 for H0a and H0b, with

alpha risks of 0.221 and 0.227, respectively. Compared with empirical standard errors, average

standard errors were similar for PSM (0.116 vs. 0.113 and 0.133 vs. 0.140 under H0a and H0b,

respectively), slightly lower for PHM (0.097 vs. 0.112 and 0.111 vs. 0.132, respectively) and lower

for FHM (0.097 vs. 0.150 and 0.109 vs. 0.169, respectively). With unbalanced treatment

allocation, the biases for PHM and FHM were higher than with balanced treatment allocation for

H0a (0.042 and 0.036, respectively) and H0b (0.125 and 0.115, respectively), as well as the alpha

risks. Compared with empirical standard errors, average standard errors were lower for PHM and

FHM. Results regarding bias, alpha risk and comparison of average and empirical standard errors

for PSM were similar to those with balanced treatment allocation.

Estimations with 0.25 weights for patients in hybrid pairs and balanced treatment allocation

showed a better control of the alpha risk for both PHM (0.057 and 0.069 for H0a and H0b,

respectively) and FHM (0.061 and 0.083, respectively). They also showed a lower difference

between empirical standard errors and average standard errors for both PHM (0.105 vs. 0.109 and

0.120 vs. 0.128 under H0a and H0b, respectively) and FHM (0.137 vs. 0.150 and 0.154 vs. 0.169,

respectively). Compared with the 0.5 weighting, the 0.25 weighting also showed a better control of

the alpha risk with unbalanced treatment allocation for both PHM (0.174 and 0.228 for H0a and

H0b, respectively) and FHM (0.243 and 0.282, respectively), as well as a lower difference between

average and empirical standard errors for both frameworks.

Table 1. Performances of matching frameworks over 1000 simulations under the null hypotheses H0a and H0b

Framework	Treatment allocation	Weighting of hybrid pairs*	H0a							H0b						
			Total pairs	Synth-treated/sim-control pairs	Sim-treated/synth-control pairs	Bias	Average standard error	Empirical standard error	Alpha risk	Total pairs	Synth-treated/sim-control pairs	Sim-treated/synth-control pairs	Bias	Standard error	Empirical standard error	Alpha risk
PSM	Balanced	-	711.3	-	-	-0.004	0.116	0.113	0.037	711.3	-	-	0.034	0.133	0.140	0.063
	Unbalanced	-	398.4	-	-	0.000	0.155	0.150	0.039	398.4	-	-	0.017	0.177	0.179	0.048
PHM	Balanced	0.5	1288.7	288.6	288.8	-0.002	0.097	0.112	0.083	1288.6	288.6	288.8	0.035	0.111	0.132	0.107
		0.25	1288.7	288.6	288.8	-0.002	0.105	0.109	0.057	1288.6	288.6	288.8	0.033	0.120	0.128	0.069
	Unbalanced	0.5	1601.4	1202.2	0.7	0.042	0.097	0.191	0.351	1601.4	1202.3	0.7	0.125	0.110	0.217	0.410
		0.25	1601.4	1202.2	0.7	0.030	0.117	0.165	0.174	1601.4	1202.3	0.7	0.097	0.132	0.189	0.228
FHM	Balanced	0.5	1999.9	999.9	1000.0	-0.003	0.097	0.150	0.221	1999.9	999.8	1000.0	0.039	0.109	0.169	0.227
		0.25	1999.9	999.9	1000.0	-0.003	0.137	0.150	0.061	1999.9	999.8	1000.0	0.039	0.154	0.169	0.083
	Unbalanced	0.5	1999.8	1600.7	399.2	0.036	0.097	0.224	0.401	1999.9	1600.7	399.2	0.115	0.109	0.251	0.469
		0.25	1999.8	1600.7	399.2	0.036	0.138	0.224	0.243	1999.9	1600.7	399.2	0.115	0.155	0.251	0.282

H0a and H0b: absence and presence of confounding, respectively. PSM: propensity-score matching of simulated patients (no GAN-generated patients). PHM:

partial hybrid (PSM with additional "hybrid pairs" of simulated and GAN-generated synthetic patients). FHM: full hybrid (matching of simulated patients with

synthetic ones). Probability of treatment allocation set to either 50% (balanced) or 20% (unbalanced). Bias: average difference between simulated and estimated log

OR. Empirical standard error: standard deviation of the log OR point estimates. Alpha risk: proportion of simulations with 95% CIs not containing 0.

Simulations under the alternative hypothesis

Results are reported in **Table 2**. Under the H1a and H1b hypotheses (absence and presence of

confusion, respectively, with a treatment effect of log OR = 0.1), the biases for usual PSM methods

with balanced treatment allocation were -0.006 and 0.028, and the estimated powers were 0.121 and

0.096, respectively. Using 0.5 weights for patients in hybrid pairs, the biases were similar for PHM

(-0.005 and 0.028, respectively), as well as for FHM (-0.009 and 0.038, respectively). Compared

with PSM, powers were higher for PHM (0.194 and 0.140, respectively) and FHM (0.302 and

0.225, respectively). PSM showed appropriate 95% CI coverage (95.3% and 94%, respectively),

while it was close for PHM (91.1% and 90.8%, respectively) and lower for FHM (79.5% and

79.6%, respectively). With unbalanced treatment allocation, performances were similar for PSM

under both H1a and H1b hypotheses, whereas bias and 95% CI coverage showed poorer

performances for both PHM and FHM.

Estimations with 0.25 weights for patients in hybrid pairs showed similar or better performances

than the 0.5 weighting regarding all performance measures for both PHM and FHM, with either

balanced or unbalanced treatment allocation. With balanced treatment allocation, 95% CI coverages

were close to the expected 95% value for both PHM (94.4% and 93.5% under H1a and H1b,

respectively) and FHM (92.7% and 92.6%, respectively).

When simulating a log OR of 0.5, the comparison of frameworks under the different scenarios led

to similar conclusions, with performances globally poorer than with log OR = 0.1

(**Supplementary Table 5**).

Table 2. Performances of matching frameworks over 1000 simulations under the alternative hypotheses with simulated log OR = 0.1

Framework	Treatment allocation	Weighting of hybrid pairs	H1a								H1b							
			Total pairs	Synth-treated/ sim-control pairs	Sim-treated/ synth-control pairs	Bias	Average standard error	Empirical standard error	power	95% CI coverage	Total pairs	Synth-treated/ sim-control pairs	Sim-treated/ synth-control pairs	Bias	Average standard error	Empirical standard error	Power	95% CI coverage
PSM	Balanced	-	711.3	-	-	-0.006	0.116	0.116	0.121	0.953	711.3	-	-	0.028	0.131	0.136	0.096	0.940
	Unbalanced	-	398.4	-	-	-0.001	0.155	0.158	0.105	0.948	398.4	-	-	0.020	0.174	0.173	0.064	0.950
PHM	Balanced	0.5	1288.7	288.6	288.8	-0.005	0.097	0.112	0.194	0.911	1288.7	288.6	288.8	0.028	0.109	0.127	0.140	0.908
		0.25	1288.7	288.6	288.8	-0.005	0.105	0.108	0.161	0.944	1288.7	288.6	288.8	0.027	0.119	0.125	0.100	0.935
	Unbalanced	0.5	1601.3	1202.2	0.7	0.048	0.097	0.198	0.327	0.657	1601.5	1202.3	0.7	0.122	0.109	0.212	0.338	0.597
		0.25	1601.3	1202.2	0.7	0.035	0.117	0.171	0.201	0.808	1601.5	1202.3	0.7	0.094	0.130	0.186	0.183	0.764
FHM	Balanced	0.5	1999.9	999.9	1000.0	-0.009	0.097	0.149	0.302	0.795	1999.9	999.9	1000.0	0.038	0.108	0.162	0.225	0.796
		0.25	1999.9	999.9	1000.0	-0.009	0.137	0.149	0.130	0.927	1999.9	999.9	1000.0	0.038	0.152	0.162	0.077	0.926
	Unbalanced	0.5	1999.7	1600.6	399.2	0.043	0.097	0.228	0.399	0.597	1999.9	1600.7	399.2	0.597	0.108	0.247	0.410	0.535
		0.25	1999.7	1600.6	399.2	0.043	0.138	0.228	0.241	0.748	1999.9	1600.7	399.2	0.110	0.153	0.247	0.232	0.708

349   H1a and H1b: absence and presence of confounding, respectively. PSM: propensity-score matching of simulated patients (no GAN-generated patients). PHM:

350   partial hybrid (PSM with additional "hybrid pairs" of simulated and GAN-generated synthetic patients). FHM: full hybrid (matching of simulated patients with

351   synthetic ones). Probability of treatment allocation set to either 50% (balanced) or 20% (unbalanced). Bias: average difference between simulated and estimated log

352   OR. Empirical standard error: standard deviation of the log OR point estimates. Power: proportion of simulations with 95% CIs not containing the simulated log

353   OR.

Evaluation of prone positioning in COVID-19 mechanically-ventilated patients

Study participants

A total of 1459 unique COVID-19 patients met the inclusion criteria, among whom 60 had unknown discharge mode. In the 1399 remaining patients, 590 belonged to the prone positioning (treated) group and 809 to the control group. The number of deaths in these groups were 226 and 254, respectively (**Figure 3**). Baseline characteristics of study participants are reported in **Supplementary Table 2.** The median age was 63 years (Q1: 55; Q3: 70), 75% were male, and common comorbidities included history of cancer (6%), hypertension (34%), renal disease (33%), and diabetes (24%). By study design, all patients were on mechanical ventilation for acute respiratory failure.

Figure 3. Flowchart for the inclusion and survival of patients from the AP-HP warehouse. RD: respiratory

distress, MV: mechanical ventilation.

Data generation

Multiple imputation was performed over the 50 baseline covariates (averaged values over the 10

imputed datasets are reported in **Supplementary Table 3**). After continuous covariates were

binarized, the 10 imputed datasets were independently submitted to the CTGAN algorithm to

generate 50,000 synthetic patients.

Quality control

Intra-variable quality, i.e. whether the model was able to reproduce the marginal distribution of

each variable in the initial cohort, was checked by graphically comparing the means and standard

deviations between observed and generated data (**Supplementary Figure 1**). The distribution of

generated values was very similar to observed data, except for renal replacement therapy (RRT),

absent in all generated patients.

Supplementary Figure 2 shows the cumulative sum of variables in observed and generated

patients, thus providing a more detailed overview of marginal distributions.

Joint distributions were checked graphically by comparing the correlograms between observed and

generated data (**Supplementary Figure 3**). As for marginal distributions, observed and generated

data showed very similar patterns of associations, except for RRT.

Matching

The same matching frameworks as those evaluated in the simulation study were used. PSM with a

0.25 caliper allowed to match an average of 471.5 patients (80.0% of patients in the treated group

and 58.3% of the control group). Both PHM and FHM were able to match all the 1399 observed

patients, using generated patients (**Table 3**). **Figure 4** compares the distribution of propensity

scores between the treated and control groups before matching and using PSM, PHM and FHM.

The use of hybrid pairs helped attain balance in measured baseline covariates between treated and

control subjects, with only 27 standard mean differences out of 63 below the 0.1 threshold without

matching, vs. 14, 11 and 7 after PSM, PHM and FHM, respectively (**Supplementary Figure 4**).

Figure 4. Histogram of propensity scores for the two treatment groups before and after matching.

Effect estimation

The OR point estimates for the effect of prone positioning on 28-day mortality were similar for all

matching frameworks: 1.33 (0.97, 1.32), 1.28 (1.00, 1.65) and 1.22 (0.91, 1.64) for PSM, PHM and

FHM, respectively (**Table 3**). No association was significant at the 0.05 threshold.

Table 3. Estimation of the association of prone positioning with 28-day mortality of COVID-19 patients in

respiratory distress.

	Total pairs	**Synth-treated/obs-control pairs**	**Obs-treated/synth-control pairs**	**OR (95% CI)**	**P-value**
PSM	471.5	0	0	1.33 (0.97, 1.32)	0.077
PHM	927.5	337.5	118.5	1.28 (1.00, 1.65)	0.053
FHM	1399	809	590	1.22 (0.91, 1.64)	0.180

404 PSM: propensity score matching; PHM: partial hybrid matching; FHM: full hybrid matching.

Discussion

Main findings

In this work, we explored a novel approach to augment data in causal inference analyses with GAN-

generated synthetic observations. The motivation was to address a common shortcoming of PS

matching methods: the exclusion of patients without matches in the other intervention group. By

generating synthetic patients for the under-represented strata, we hoped to include as many patients

as possible from the original sample in the analysis, thus potentially increasing statistical power and

generalizability.

Our simulation results indicate that, while GANs can indeed create very realistic synthetic patients

and prevent sample loss, the current implementation did not reliably improve causal inference

performance. In fact, naively using all GAN-generated matches led to misleadingly small p-values

standard deviations and confidence intervals, i.e. an anti-conservative analysis. This was evidenced

by the inflated type I error under null scenarios and under-coverage of confidence intervals under

alternatives. The fundamental issue is that synthetic data do not add independent information – they

are derived from the original data and essentially replicate patterns from it. If treated as entirely new

observations, they cause the analysis to overcount evidence, resulting in overstated precision. Down-

weighting pairs with synthetic observations limited the type I error, yet no scenario permitted to

obtain lower type I and type II error rates than PSM simultaneously.

The real-world application echoed these findings. In the COVID-19 prone positioning study, PSM

excluded a large number of patients (in this case, many controls who had much lower risk and thus

were unmatched). PHM was able to include nearly all patients by pairing them with GAN-synthetic

counterparts, roughly doubling the matched sample size. However, the treatment effect estimates

remained essentially unchanged and there was still no statistically significant effect of prone

positioning on mortality with either approach. FHM, which used exclusively synthetic matching, did

not improve precision at all in this case. We suspect this is because the GAN introduced noise and

slight distortions in the data that offset the gains from augmented sample size. Indeed, our GAN had

excellent performance in reproducing marginal distributions, but subtle discrepancies in joint

distributions or extreme values could have diluted the treatment contrast. Importantly, even if PHM

had yielded a p-value <0.05, one would need to be cautious in interpretation, as the nominal

significance might be driven by underestimated uncertainty.

Other differences between the three frameworks might also be explained by the estimators: in causal

inference, the average treatment effect (ATE) estimates the average impact of a treatment across the

entire population, regardless of who actually received it. In contrast, the average treatment effect on

the treated (ATT) focuses only on those who were treated, measuring the treatment's effect

specifically for them. By discarding control patients useless to match treated ones, PSM usually

follows an ATT approach (when most patients in the sample are not treated). By considering all

patients in the original sample, hybrid methods are closer to an ATE approach. We expected this

difference would reveal the interest of hybrid methods in the unbalanced scenario, as the gain in

sample size was the highest, yet results were quite similar to the balanced scenario.

Challenges of augmented data in causal inference

Our study highlights several challenges and considerations for future efforts.

First, regarding variance estimation: The most prominent issue is how to correctly estimate

uncertainty when synthetic data are used. Standard formulas assume independent samples; here that

assumption is violated. We applied a simple weighting heuristic as a proxy for more formal variance

correction; alternative approaches could involve analytical derivation of the effective sample size of

GAN-augmented data or using bootstrapping techniques that resample the original data and

regenerate synthetic data in each bootstrap, which would be computationally heavy. Without

adjustment, one risks reporting overly tight confidence intervals and exaggerated significance. Any

practical application of GANs in inference must address this, possibly by scaling standard errors

upward or using sandwich estimators that account for the two-stage generation process.

Second, regarding the bias vs. variance trade-off: Interestingly, we did not observe notable

systematic bias in point estimates due to GAN usage. However, one can imagine scenarios where the

GAN could introduce bias: for instance, if the GAN fails to capture an interaction between treatment

and a covariate that affects outcome, the synthetic data might distort the effect estimate.

Third, regarding GAN limitations: The performance of this strategy ultimately depends on the

quality of the GAN-generated data. If the GAN perfectly reproduced the joint distribution of

covariates and the treatment assignment mechanism, then synthetic controls would be as reliable as

real ones (assuming no unmeasured confounding). However, current GANs have limitations.

Although their use for image generation is showing very satisfactory results, [35, 36] our results

highlight their limits for discrete and tabular data, which corroborates recent research on the

architecture we used. [37] They may struggle with high-dimensional, sparse data or with capturing

complex correlations. For example, generating a realistic combination of multiple comorbidities and

lab trends that correspond to a severe COVID patient is a tall order. Our chosen model, CTGAN, is

state-of-the-art for tabular data, but even it might not encode all clinical logic. GANs can also suffer

from mode collapse (not representing the full diversity of the data) or can produce nonsensical

outliers. In our synthetic data checks, we noticed a few minor inconsistencies (like a synthetic

patient with an unusual combination of rare features that was not seen in reals, but these were rare).

If GANs inadvertently violate clinical constraints or logical relationships, those could confound the

matching. Recent studies concur that generating complex, multimodal health records with full

fidelity is an open challenge. [22] For instance, Ghosheh et al. point out that current GAN

approaches cannot yet generate richly detailed patient records across multiple data types (labs,

images, notes) in a coherent way. [38] In our context, we only dealt with tabular ICU data and still

faced difficulties. Thus, applying GANs in more complicated causal questions (e.g. longitudinal

treatments, time-varying confounding) will be even more challenging.

Fourth, regarding generative model improvements: There is active research into better generative

models for healthcare data. Our negative findings don't mean GANs will never be useful – rather, it

highlights that methodological advances are needed. One avenue is to incorporate domain

knowledge or constraints into GAN training. Integrating clinical rules could prevent unrealistic

combinations. [22] This could be achieved via constrained GAN objectives or post-processing

filters. Additionally, non-GAN generative methods like Bayesian models or imputation models

could be explored as alternatives for generating counterfactuals. Regression models [39], CART

models that have recently shown more promising results than current GANs [37], or transformers

fine-tuned for tabular data [40] may be considered. Other approaches might avoid some pitfalls of

GANs but have their own modeling assumptions. [41]

Fifth, regarding the use of synthetic data as external control arms: The idea of using external or

synthetic controls is gaining traction in regulatory settings (e.g. single-arm trials augmented by real-

world data controls). [23] The experience here aligns with cautions raised in that context: quality

and comparability of the external data (or synthetic data) are paramount. Regulators emphasize

thorough validation of whether an external control truly "mirrors" a randomized control. In our case,

we see that even though our GAN synthetic patients passed basic similarity checks, using them

required statistical adjustment to avoid bias. This reinforces that synthetic data should be used with

great care in causal analyses, and methods to quantify uncertainties are needed.

Limitations

This study has several limitations. First, our simulation scenarios, while diverse, may not encompass

all situations. We used relatively low-dimensional data (six covariates) and simple logistic models.

In more complex simulations (e.g. nonlinear effects, high-dimensional covariate space, presence of

interactions), the performance of the evaluated matching frameworks might differ. Second, we

focused on one GAN model (CTGAN). It is possible that other generative models (e.g. variational

autoencoders, normalizing flows, or newer transformer-based generators) could produce higher

fidelity synthetic data and improve results. Third, in the prone positioning case study, there may be

unmeasured confounders that no amount of GAN matching can fix. Our methods, like any PS

method, assume no residual confounding, whereas the prone positioning example is complicated by

indication bias not captured by the documented covariates. Thus, one must remember that synthetic

data augmentation addresses data overlap and sample size issues, not fundamental confounding.

Finally, our weighting strategy for synthetic data, while pragmatic, lacks a rigorous theoretical

foundation and an optimal weighting or a different variance estimator might be derived in future

work.

Future research

We encourage further methodological research on how to integrate augmented data into causal

analyses. For instance, developing causal inference algorithms that internally generate synthetic

counterfactuals and adjust for their uncertainty could be fruitful. There is ongoing work on bridging

GANs with causal modeling – some propose training GANs not just to match data distribution, but

also to ensure that causal relationships (e.g. conditional independencies, propensity score

distributions) are preserved. [42] Additionally, the use of large language models (LLMs) and

transformers for data synthesis is emerging as an alternative to GANs. Early evidence suggests

LLMs might generate mixed-type data with fewer mode collapse issues, which could potentially

improve tabular data synthesis quality. [22] From an application perspective, more case studies in

different clinical settings might be useful. Scenarios with major indication bias and limited sample

size may uncover situations where the advantages of data augmentation might overcome its

drawbacks.

Conclusions

Our study provides a cautious take on the use of GAN-generated synthetic data for causal inference

in medicine. GANs show great promise in creating realistic patient data and can help keep more

patients in causal inference with propensity score matching. However, simply adding GAN-

generated patients is not recommended without careful adjustments, as it can lead to erroneous

confidence in results. In our simulations, standard PSM still provided more reliable control of type I

error and coverage than unadjusted hybrid approaches. We advise that researchers proceed carefully

when considering synthetic data augmentation: validate that synthetic records are indistinguishable

from real in key covariates, ensure balance on propensity scores is achieved, and adjust the analysis

to account for the nature of the generated data. As generative AI techniques evolve, we anticipate

they will become more robust and perhaps eventually play a routine role in observational studies.

However, the use of GANs in causal inference still requires skepticism and rigorous assessment, to

which our work contributes by highlighting pitfalls and suggesting practical solutions. With

continued research at the intersection of machine learning and causal inference, we remain

optimistic that future innovations will unlock the full potential of synthetic data while maintaining

the rigor of causal analysis.

List of abbreviations

RCT – Randomized Controlled Trial

EHR – Electronic health record

PS – Propensity Score

IPTW – Inverse Probability of Treatment Weighting

PSM – Propensity Score Matching

GAN – Generative Adversarial Network

CTGAN – Conditional Tabular GAN

SDV – Synthetic Data Vault

PHM – Partial Hybrid Matching

FHM – Full Hybrid Matching

CI – Confidence Interval

OR – Odds Ratio

ARDS – Acute Respiratory Distress Syndrome

ICU – Intensive Care Unit

AP-HP – Assistance Publique – Hôpitaux de Paris

ICD-10 – International Classification of Diseases, 10th Revision

CCAM – Classification Commune des Actes Médicaux

Insee –Institut national de la statistique et des études économiques (National Institute of Statistics

and Economic Studies)

RRT – Renal Replacement Therapy

ATE – Average Treatment Effect

ATT – Average Treatment effect on the Treated

LLM – Large language models

Declarations

Ethics approval and consent to participate

This multicenter, non-interventional research is based on care data collected during patients' hospital stays at

AP-HP (reference: 200016 PREDIREA-COVID). It was approved by the Scientific and Ethics Committee of

the AP-HP Health Data Warehouse (EDS), which is authorized by the French National Commission on

Informatics and Liberty (CNIL) to review such non-interventional, data-based studies that do not require

informed consent. The research does not involve processing indirectly identifiable data, linking with external

data sources, or conducting long-term patient follow-up.

Consent for publication

Not applicable.

Availability of data and materials

The data used in the study are not publicly available due the confidentiality of data from patient

records, even after de-identification. However, access to the AP-HP data warehouse's raw data can

be granted following the process described on its website www.eds.aphp.fr, contacting the Scientific

and Ethics Commity at secretariat.cse@aphp.fr. A prior validation of the access by the local

institutional review board is required. In the case of non-APHP researchers, the signature of a

collaboration contract is moreover mandatory.

Competing interests

The authors declare that they have no competing interests.

Funding

Authors' contributions

BB, BG, FC and NL designed the study. BB and NL conducted the analyses and

drafted the manuscript. All authors revised it critically and approved the final

version.

Acknowledgements

References

[1]   Hill AB. The clinical trial. N Engl J Med. 1952;247(4):113-9. doi:10.1056/nejm195207242470401.

[2]   Simon SD. Is the randomized clinical trial the gold standard of research? J Androl. 2001;22(6):938-

43. doi:10.1002/j.1939-4640.2001.tb03433.x.

[3]   Bondemark L, Ruf S. Randomized controlled trial: the gold standard or an unobtainable fallacy? Eur

J Orthod. 2015;37(5):457-61. doi:10.1093/ejo/cjv046.

[4]   Stuart EA, Bradshaw CP, Leaf PJ. Assessing the generalizability of randomized trial results to target

populations. Prev Sci. 2015;16(3):475-85. doi:10.1007/s11121-014-0513-z.

[5]   Dash S, Shakyawar SK, Sharma M, Kaushik S. Big data in healthcare: management, analysis and

future prospects. J Big Data. 2019;6(1). doi:10.1186/s40537-019-0217-0.

[6]   Doyle-Lindrud S. The evolution of the electronic health record. Clin J Oncol Nurs. 2015;19(2):153-4.

doi:10.1188/15.CJON.153-4.

[7]   Shiffrin RM. Drawing causal inference from big data. Proc Natl Acad Sci U S A. 2016;113(27):7308-

9. doi:10.1073/pnas.1608845113.

[8]   Hernán MA, Hsu J, Healy B. A second chance to get causal inference right: a classification of data

science tasks. Chance. 2019;32(1):42-9. doi:10.1080/09332480.2019.1579578.

[9]   Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not

available. Am J Epidemiol. 2016;183(8):758-64. doi:10.1093/aje/kwv254.

[10]   Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314(15):1637.

doi:10.1001/jama.2015.13480.

[11]   Chesnaye NC, Stel VS, Tripepi G, Dekker FW, Fu EL, Zoccali C, et al. An introduction to inverse

probability of treatment weighting in observational research. Clin Kidney J. 2021;15(1):14-20.

doi:10.1093/ckj/sfab158.

[12]   Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for

causal effects. Biometrika. 1983;70(1):41-55. doi:10.1093/biomet/70.1.41.

[13]   Benedetto U, Head SJ, Angelini GD, Blackstone EH. Statistical primer: propensity score matching

and its alternatives. Eur J Cardiothorac Surg. 2018;53(6):1112-7. doi:10.1093/ejcts/ezy167.

[14]   Bakker LJ, Goossens LMA, O'Kane MJ, Uyl-de Groot CA, Redekop WK. Analysing electronic

health records: the benefits of target trial emulation. Health Policy Technol. 2021;10(3):100545.

doi:10.1016/j.hlpt.2021.100545.

[15]   Nuttall GA, Houle TT. Liars, damn liars, and propensity scores. Anesthesiology. 2008;108(1):3-4.

doi:10.1097/01.anes.0000296718.35703.20.

[16]   Hajage D, Tubach F, Steg PG, Bhatt DL, De Rycke Y. On the use of propensity scores in case of rare

exposure. BMC Med Res Methodol. 2016;16(1). doi:10.1186/s12874-016-0135-1.

[17]   Gu J, Wang Z, Kuen J, Ma L, Shahroudy A, Shuai B, et al. Recent advances in convolutional neural

networks. Pattern Recognit. 2018;77:354-77. doi:10.1016/j.patcog.2017.10.013.

[18]   Sze V, Chen YH, Yang TJ, Emer JS. Efficient processing of deep neural networks: a tutorial and

survey. Proc IEEE. 2017;105(12):2295-323. doi:10.1109/JPROC.2017.2761740.

[19]   Goodfellow IJ, Pouget-Abadie J, Mirza M, Xu B, Warde-Farley D, Ozair S, et al. Generative

adversarial networks. arXiv. 2014 Jun [cited 2025 Jan 10]. Available from: http://arxiv.org/abs/1406.2661.

[20]   Creswell A, White T, Dumoulin V, Arulkumaran K, Sengupta B, Bharath AA. Generative adversarial

networks: an overview. IEEE Signal Process Mag. 2018;35(1):53-65. doi:10.1109/MSP.2017.2765202.

[21]   Xu L, Veeramachaneni K. Synthesizing tabular data using generative adversarial networks. arXiv.

2018 Nov [cited 2025 Jan 10]. Available from: http://arxiv.org/abs/1811.11264.

[22]   Smolyak D, Bjarnadóttir MV, Crowley K, Agarwal R. Large language models and synthetic health

data: progress and prospects. JAMIA Open. 2024;7(4). doi:10.1093/jamiaopen/ooae114.

[23] Umesh C, Mahendra M, Bej S, Wolkenhauer O, Wolfien M. Challenges and applications in

generative AI for clinical tabular data in physiology. Pflugers Arch. 2024;477(4):531-42.

doi:10.1007/s00424-024-03024-w.

[24] Xu L, Skoularidou M, Cuesta-Infante A, Veeramachaneni K. Modeling tabular data using conditional

GAN. arXiv. 2019 Oct [cited 2025 Jan 10]. Available from: http://arxiv.org/abs/1907.00503.

[25] Hernandez M, Epelde G, Alberdi A, Cilla R, Rankin D. Synthetic data generation for tabular health

records: a systematic review. Neurocomputing. 2022;493:28-45. doi:10.1016/j.neucom.2022.04.053.

[26] Bourou S, El Saer A, Velivassaki TH, Voulkidis A, Zahariadis T. A review of tabular data synthesis

using GANs on an IDS dataset. Information. 2021;12(9):375. doi:10.3390/info12090375.

[27] Patki N, Wedge R, Veeramachaneni K. The synthetic data vault. In: Proceedings of the 3rd IEEE

International Conference on Data Science and Advanced Analytics (DSAA); 2016 Dec; Montreal, Canada. p.

399-410. doi:10.1109/DSAA.2016.49.

[28] Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal

inference. J Stat Softw. 2011;42(8). doi:10.18637/jss.v042.i08.

[29] Guérin C, Reignier J, Richard JC, Beuret P, Gacouin A, Boulain T, et al. Prone positioning in severe

acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159-68. doi:10.1056/NEJMoa1214103.

[30] Daniel C. La recherche clinique à partir d'entrepôts de données. L'expérience de l'Assistance

Publique – Hôpitaux de Paris (AP–HP) à l'épreuve de la pandémie de Covid-19. Rev Med Interne.

2020;41(5):303-7. doi:10.1016/j.revmed.2020.04.005.

[31] Admon AJ, Gershengorn HB, Zhang S, Luo Y, Dai Y, Churpek MM, et al. Consensus elements for

observational research on COVID-19-related long-term outcomes. Medicine (Baltimore).

2022;101(46):e31248. doi:10.1097/MD.0000000000031248.

[32]   Zhang JJ, Dong X, Liu GH, Gao YD. Risk and protective factors for COVID-19 morbidity, severity,

and mortality. Clin Rev Allergy Immunol. 2023;64(1):90-107. doi:10.1007/s12016-022-08921-5.

[33]   van Buuren S. Flexible imputation of missing data. 2nd ed. Boca Raton: Chapman and Hall/CRC;

2018. doi:10.1201/9780429492259.

[34]   Audigier V, White IR, Jolani S, Debray TPA, Quartagno M, Carpenter JR, et al. Multiple imputation

for multilevel data with continuous and binary variables. Stat Sci. 2018;33(2):160-83. doi:10.1214/18-sts646.

[35]   Karras T, Aila T, Laine S, Lehtinen J. Progressive growing of GANs for improved quality, stability,

and variation. arXiv. 2018 Feb [cited 2025 Jan 10]. Available from: http://arxiv.org/abs/1710.10196.

[36]   Brock A, Donahue J, Simonyan K. Large scale GAN training for high fidelity natural image

synthesis. arXiv. 2019 Feb [cited 2025 Jan 10]. Available from: http://arxiv.org/abs/1809.11096.

[37]   Pathare A, Mangrulkar R, Suvarna K, Parekh A, Thakur G, Gawade A. Comparison of tabular

synthetic data generation techniques using propensity and cluster log metric. Int J Inf Manag Data Insights.

2023;3(2):100177. doi:10.1016/j.jjimei.2023.100177.

[38]   Ghosheh GO, Li J, Zhu T. A survey of generative adversarial networks for synthesizing structured

electronic health records. ACM Comput Surv. 2024;56(6):1-34. doi:10.1145/3636424.

[39]   Nowok B, Raab GM, Dibben C. synthpop: bespoke creation of synthetic data in R. J Stat Softw.

2016;74(11). doi:10.18637/jss.v074.i11.

[40]   Solatorio AV, Dupriez O. REaLTabFormer: generating realistic relational and tabular data using

transformers. arXiv. 2023 Feb [cited 2025 Jan 10]. Available from: http://arxiv.org/abs/2302.02041.

[41]   Gonzales A, Guruswamy G, Smith SR. Synthetic data in health care: a narrative review. PLOS Digit

Health. 2023;2(1):e0000082. doi:10.1371/journal.pdig.0000082.

[42] Shi J, Wang D, Tesei G, Norgeot B. Generating high-fidelity privacy-conscious synthetic patient data

for causal effect estimation with multiple treatments. Front Artif Intell. 2022;5:918813.

doi:10.3389/frai.2022.918813.